Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR1D | P28221 | 2/20 | 0.55 |
| ▸ | HTR1B | P28222 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25859302 | 0.84 | MEN1 (0.53) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL3173523 | 0.81 | HTR2A (0.61) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL3163672 | 0.81 | MEN1 (0.58) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL28392291 | 0.81 | MEN1 (0.62) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL13915153 | 0.81 | MEN1 (0.62) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL31121215 | 0.81 | MEN1 (0.62) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL1521032 | 0.81 | MEN1 (0.62) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL12791843 | 0.80 | HTR2A (0.58) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL18073439 | 0.80 | PKM (0.58) | MEN1KMT2ACYP3A4GPR84MAPT | |
| Hydrochloric Acid SCHEMBL1520691 | 0.79 | PMP22 (0.61) | MEN1KMT2ACYP3A4GPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688179-A1 | ISOTHIOCYANATE CONTAINING BRASSICACEAE | Commonwealth Scientific and Industrial Research Organisation (AU) | 2020-08-05 | — | — | EP | claimed |
| WO-2019060963-A1 | ISOTHIOCYANATE CONTAINING BRASSICACEAE PRODUCTS AND METHOD OF PREPARATION THEREOF | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2019-04-04 | — | — | WO | claimed |
| US-20150164860-A1 | ANTICANCER TREATMENT METHODS INVOLVING ANALOGS AND DERIVATIVES OF 3-(2-SUBSTITUTED-ETHYL) INDOLE COMPOUNDS | TUSKEGEE UNIVERSITY (US) | 2015-06-18 | — | — | US | claimed |
| EP-2344114-A2 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | The Procter & Gamble Company (US) | 2011-07-20 | — | — | EP | claimed |
| EP-2215239-A1 | TRANSGENIC PLANTS HAVING ALTERED LEVELS OF AROMATIC AMINO ACIDS AND METABOLITES DERIVED THEREFROM | Yeda Research And Development Company Ltd. (IL) | 2010-08-11 | — | — | EP | claimed |
| WO-2010054343-A2 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | THE PROCTER & GAMBLE COMPANY (US) | 2010-05-14 | — | — | WO | claimed |
| US-20100120871-A1 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | THE PROCTER & GAMBLE COMPANY | 2010-05-13 | — | — | US | claimed |
| EP-1030663-B1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS (US) | 2010-03-10 | — | — | EP | claimed |
| WO-2009072118-A1 | TRANSGENIC PLANTS HAVING ALTERED LEVELS OF AROMATIC AMINO ACIDS AND METABOLITES DERIVED THEREFROM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-06-11 | — | — | WO | claimed |
| US-6613792-B1 | Treatment of premenstrual syndrome and menopause | DESIGNED NUTRITIONAL PRODUCTS, INC. | 2003-09-02 | — | — | US | claimed |
| EP-1030663-A4 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001008637-A2 | TREATMENT OF PREMENSTRUAL SYNDROME AND MENOPAUSE | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 2001-02-08 | — | — | WO | claimed |
| EP-1030663-A1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | Designed Nutritional Products Inc. (US) | 2000-08-30 | — | — | EP | claimed |
| US-5895787-A | Treatment of fibromyalgia and related disorders | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 1999-04-20 | — | — | US | claimed |
| WO-1999017768-A1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 1999-04-15 | — | — | WO | claimed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| CN-119998926-A | Polishing liquid for CMP, polishing liquid set for CMP and polishing method | 株式会社力森诺科 | 2025-05-13 | — | — | CN | disclosed |
| US-5895787-A | Treatment of fibromyalgia and related disorders | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 1999-04-20 | — | — | US | disclosed |
| WO-1999017768-A1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999017768-A1 | TREATMENT OF FIBROMYALGIA AND RELATED DISORDERS | DESIGNED NUTRITIONAL PRODUCTS, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164860-A1 | ANTICANCER TREATMENT METHODS INVOLVING ANALOGS AND DERIVATIVES OF 3-(2-SUBSTITUTED-ETHYL) INDOLE COMPOUNDS | MCL1, BAD, API5 | MEN1 2451/4885KMT2A 1698/4885CYP3A4 2379/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | MEN1 2589/4885KMT2A 366/4885CYP3A4 4676/4885 |
| US-20100120871-A1 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | SHH, FSCN1, CUTA | MEN1 251/4885KMT2A 2232/4885CYP3A4 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.